medigraphic.com

2018, Number 3

<< Back Next >>

Enf Infec Microbiol 2018; 38 (3)

Rubella vaccine elicited a combined cellular and humoral immune response in adults

García LML, Wong CRM

Language: Spanish
References: 41
Page: 72-77
PDF size: 166.23 Kb.


ABSTRACT

Introduction. Vaccination with rubella increases IgG antibodies; however, information is limited about the cellular immune response in healthy adults. Humoral (HI) and cellular (CI) immune response were characterized in healthy adults immunized with rubella vaccine.
Material and Methods. Twenty healthy adults, from 20 to 34 years old received Priorix (MMR) vaccine. HI was measured by ELISA and CI was measured by a specific lymphoproliferation assay, before and at one and three months after vaccination. Clinical symptoms were recorded.
Results. Seroconversion was observed in two seronegative subjects (20%) in the absence of CI. The overall seroconversion defined as seronegative to seropositive or a fourfold increase from basal titers was 20% (4/20). Seroprevalence for rubella was 90% (18/20) and seropositivity was 100% three months post-vaccination (p = 0.24). The percentage of adults with a stimulation index (Si) ›3 and mean SI ± SE was 40% and 3.37 ± 0.49 before, 40% and 3.63 ± 0.84 and 50% and 3.39 ± 0.44 one and three months after vaccination, respectively. A booster CI response in three immunized adults with previous protective titers was observed.
Conclusions. Rubella seropositivity in our study was 90%. We observed a booster CI response in three subjects, without increase in IgG titers. In the two seronegative subjects there was a seroconversion in the absence of CI. There was no antibody booster response in subjects with high titers of antibodies. The immunization with rubella vaccine in healthy adults can elicit a booster HI and/or CI.


REFERENCES

  1. Banatvala, J.E. y Brown, D.W., “Rubella”, Lancet, 2004, 363 (9415): 1127-1137.

  2. Cutts, F.T., Robertson, S.E., Díaz-Ortega, J.L. y Samuel, R., “Control of rubella and congenital rubella syndrome (crs) in developing countries, Part 1: Burden of disease from crs, Bulletin of the World Health Organization, 1997, 75 (1): 55-68.

  3. Mendis, L., “Susceptibility to rubella virus among Sri Lankan women”, The Ceylan Medical Journal, 1989, 34 (2): 73-75.

  4. Lee, J.Y. y Bowden, D.S., “Rubella virus replication and links to teratogenicity”, Clinical Microbiology Reviews, 2000, 13 (4): 571-587.

  5. Salisbury, D.M. y Savingkh, A.L., “Rubella and congenital rubella syndrome in developing countries”, epi Global Advisory Group Meeting, Antalya, Turquía, 1991.

  6. Robertson, S.E., Featherstone, D.A., Gacic-Dobo, M. y Hersh, B.S., “Rubella and congenital rubella syndrome: global update”, Revista Panamericana de Salud Pública, 2003, 14 (5): 306-315.

  7. O’Shea, S., Woodward, S., Best, J.M., Banatvala, J.E., Holzel, H. y Dudgeon, J.A., “Rubella vaccination: persistence of antibodies for 10-21 years”, Lancet, 1988, 2 (8616): 909.

  8. Reef, S.E., Frey, T.K., Theall, K., Abernathy, E., Burnett, C.L., Icenogle, J. et al., “The changing epidemiology of rubella in the 1990s: on the verge of elimination and new challenges for control and prevention”, jama, 2002, 287 (4): 464-472.

  9. Spika, J.S., Wassilak, S., Pebody, R., Lipskaya, G., Deshevoi, S., Guris, D. et al., “Measles and rubella in the World Health Organization European region: diversity creates challenges”, The Journal of Infectious Diseases, 2003, 187 Suppl 1: S191-197.

  10. World Health Organization, disponible en: http://apps. who.int/gho/data/view.main.1520_57.

  11. National for C Clinical Laboratory Standards, en nccls document 1/lab-t, vol. 12, Villanova PA, National Committee for Clinical Laboratory Standards, 1992, pp. 1-3.

  12. Skendzel, L.P., “Rubella immunity. Defining the level of protective antibody”, American Journal of Clinical Pathology, 1996, 106 (2): 170-174.

  13. Steele, R.W., Hensen, S.A., Vincent, M.M., Fuccillo, D.A. y Bellanti, J.A., “Development of specific cellular and humoral immune responses in children immunized with live rubella virus vaccine”, The Journal of Infectious Diseases, 1974, 130 (5): 449-453.

  14. Vesikari, T. y Buimovici-Klein, E., “Lymphocyte responses to rubella antigen and phytohemagglutinin after administration of the ra 27/3 strain of live attenuated rubella vaccine”, Infection and Immunity, 1975, 11 (4): 748-753.

  15. Lalla, M., Vesikari, T. y Virolainen, M., “Lymphoblast proliferation and humoral antibody response after rubella vaccination”, Clin Exp Immunol, 1973, 15 (2): 193-202.

  16. Mitchell, L.A., Ho, M.K., Rogers, J.E., Tingle, A.J., Marusyk, R.G., Weber, J.M. et al., “Rubella reimmunization: comparative analysis of the immunoglobulin g response to rubella virus vaccine in previously seronegative and seropositive individuals”, Journal of Clinical Microbiology, 1996, 34 (9): 2210-2218.

  17. Rossier, E., Phipps, P.H., Polley, J.R. y Webb, T., “Absence of cell-mediated immunity to rubella virus 5 years after rubella vaccination”, Canadian Medical Association Journal, 1977, 116 (5): 481-484.

  18. Díaz-Ortega, J.L., Meneses-Reyes, C.D. y Palacios-Martínez, M., “Incidencia y patrones de transmisión de rubéola en México”, Salud Pública Mex, 2007, 49 (5): 337-344.

  19. Kim, A.J. y Roses, P.M., “Elimination of rubella and congenital rubella sindrome in the Americas: another opportunity to address inequalities in health”, Pan Am J Public Health, 2004, 15: 145-146.

  20. Consejo Nacional de Vacunación, Manual de procedimientos técnicos de vacunación, actualización 2003, Secretaría de Salud, México.

  21. Norma Oficial Mexicana NOM-036-SSA2-2002, para prevención y control de enfermedades, aplicación de vacunas, toxoides, sueros, antitoxinas e inmunoglobulinas en el humano, Diario Oficial de la Federación, México, 2001.

  22. cenavece, Anuarios estadísticos dgae, Sistema especial epv, 2007.

  23. Direccion General de Epidedmiología, Anuario de Morbilidad Nacional, 2017, disponible en: www.epidemiologia. salud.gob.mx/anuario/html/morbilidad_nacional. html. Consultado: febrero de 2018.

  24. Tischer, A. y Gerike, E., “Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella”, Vaccine, 2000, 18 (14): 1382-1392.

  25. Johnson, C.E., Kumar, M.L., Whitwell, J.K., Staehle, B.O., Rome, L.P., Dinakar, C. et al., “Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years”, The Pediatric Infectious Disease Journal, 1996, 15 (8): 687-692.

  26. Schwarzer, S., Reibel, S., Lang, A.B., Struck, M.M., Finkel, B., Gerike, E. et al., “Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines”, Vaccine, 1998, 16 (2-3): 298-304.

  27. Schuster, V., Otto, W., Maurer, L., Tcherepnine, P., Pfletschinger, U., Kindler, K. et al., “Immunogenicity and safety assessments after one and two doses of a refrigerator- stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life”, The Pediatric infectious Disease Journal, 2008, 27 (8): 724-730.

  28. Fernández de Castro, B.J., Rincón Gallardo, H., Álvarez y Muñoz, M.T., Partida Sánchez, L.A.E. y Santos, J.I., “Evaluation of immunogenicity and side effects of triple viral vaccine (mmr) in adults, given by two routes: subcutaneous and respiratory (aerosol)”, Vaccine, 2005, 23: 1079-1084.

  29. Hillary, I.B. y Griffith, A.H., “Persistence of rubella antibodies 15 years after subcutaneous administration of Wistar 27/3 strain live attenuated rubella virus vaccine”, Vaccine, 1984, 2 (4): 274-276.

  30. Macías-Hernández, A.E., Ponce de León, S., Muñoz- Barrett, J.M., López-Jiménez, F., Cano-Castro, A., Vera-Pena, A. et al., “The seroepidemiology of rubella in a female population of reproductive age in Leon, Guanajuato”, Salud Pública de México, 1993, 35 (4): 339-344.

  31. Villaseñor-Sierra, A., Santos-Preciado, J.I., Álvarez-Muñoz, M.T., Rivas-García, M.E., Martínez-Sandoval, F. y Falcón-Franco, M.A., “Antibody development and frequency of events temporarily associated with measles and rubella vaccines among university health personnel in Jalisco”, Gac Med Mex, 2005, 141 (6): 455-459.

  32. Sepúlveda-Amor, J., Valdespino-Gómez, J.L., García-García, M.L., Bennett, J., Islas-Romero, R., Echániz-Avilés, G. et al., “A randomized trial demonstrating successful boosting responses following simultaneous aerosols of measles and rubella (mr) vaccines in school age children”, Vaccine, 2002, 20 (21-22): 2790-2795.

  33. Kauffman, C.A., Phair, J.P., Linnemann, C.C., Jr. y Schiff, G.M., “Cell-mediated immunity in humans during viral infection. I. Effect of rubella on dermal hypersensitivity, phytohemagglutinin response, and t lymphocyte numbers”, Infection and Immunity, 1974, 10 (1): 212-215.

  34. Morag, A., Morag, B., Bernstein, J.M., Beutner, K. y Ogra, P.L., “In vitro correlates of cell-mediated immunity in human tonsils after natural or induced rubella virus infection”, The Journal of Infectious Diseases, 1975, 131 (4): 409-416.

  35. Honeyman, M.C., Forrest, J.M. y Dorman, D.C., “Cell- mediated immune response following natural rubella and rubella vaccination”, Clinical and Experimental Immunology, 1974, 17 (4): 665-671.

  36. Kanra, G.Y. y Vesikari, T., “Cytotoxic activity against rubella-infected cells in the supernatants of human lymphocyte cultures stimulated by rubella virus”, Clin Exp Immunol, 1975, 19 (1): 17-32.

  37. Vesikari, T., Kanra, G.Y., Buimovici-Klein, E., y Cooper, L.Z., “Cell-mediated immunity in rubella assayed by cytotoxicity of supernatants from rubella virus-stimulated human lymphocyte cultures”, Clin Exp Immunol, 1975, 19 (1): 33-43.

  38. Toyoda, M,, Ihara, T., Nakano, T., Ito, M. y Kamiya, H., “Expression of interleukin-2 receptor alpha and cd45ro antigen on t lymphocytes cultured with rubella virus antigen, compared with humoral immunity in rubella vaccinees”, Vaccine, 1999, 17 (15-16): 2051-2058.

  39. Heigl, Z., Wasserman, J. y Forsgren, M., “In vitro lymphocyte reactivity to rubella antigen following vaccination”, Scandinavian Journal of Infectious Diseases, 1980, 12 (1): 13-20.

  40. Tingle, A.J., Chantler, J.K., Kettyls, G.D., Larke, R.P. y Schulzer, M., “Failed rubella immunization in adults: association with immunologic and virological abnormalities”, The Journal of Infectious Diseases, 1985, 151 (2): 330-336.

  41. Mitchell, L.A., Tingle, A.J., Decarie, D. y Shukin, R., “Identification of rubella virus t-cell epitopes recognized in anamnestic response to ra 27/3 vaccine: associations with boost in neutralizing antibody titer”, Vaccine, 1999, 17 (19): 2356-2365.




2020     |     www.medigraphic.com